Can a simple blood test predict dangerous side effects of immunotherapy?

NCT ID NCT03409016

Ongoing Knowledge-focused Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This pilot study is looking for biomarkers in the blood that might predict which cancer patients will develop immune-related side effects from immune checkpoint inhibitors. Researchers will compare blood samples from 69 patients with metastatic cancer before and during treatment. The goal is to find early warning signs that could help doctors manage side effects better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which cancer patients are at higher risk for immune-related side effects from checkpoint inhibitors.
What could go wrong: This is a small, early pilot study (69 people) that only looks for markers—it does not test a new treatment. The findings may not apply to all cancer types or treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm metastatic neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER METASTATIC CANCER

Contacts and locations

Locations

University of Colorado Denver

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.